Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Conditions:   NSCLC Stage IV;   NSCLC, Recurrent Intervention:   Drug: Atezolizumab Sponsors:   University of Kansas Medical Center;   parkview cancer institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials